Introduction: Erlotinib is useful in advanced non-small cell lung cancer although compliance and efficacy are diminished by skin rash in a high proportion of patients, often necessitating dose reduction or drug withdrawal. No effective treatment for the rash is available. Methods: We carried out a preliminary investigation on isotretinoin and clindamycin. Among 56 advanced lung cancer patients treated with erlotinib, 31 (53%) developed rash. Seven (35%) of the 20 G2/G3 cases agreed to treatment with clindamycin (450 mg/d, days 1-10; 300 mg/d, days 11-20) plus isotretinoin (20 mg/d, days 11-20) after being informed of the experimental nature of the combination. Results: In 6 of 7 (86%) patients, the rash resolved (G1/G0) without dose reduction; in the other patient (G3), the erlotinib dose also had to be reduced. Median time to resolution was 14 days (range 7-20 days). No rash-treatment adverse events occurred during 20 days of administration. Conclusions: Isotretinoin plus clindamycin promises to be the first effective treatment for erlotinib rash and is being tested further

Bidoli, P., Cortinovis, D., Colombo, I., Crippa, A., Cicchiello, F., Villa, F., et al. (2010). Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 5(10), 1662-1663 [10.1097/JTO.0b013e3181ec1729].

Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer

Bidoli P
Primo
;
Cazzaniga ME;
2010

Abstract

Introduction: Erlotinib is useful in advanced non-small cell lung cancer although compliance and efficacy are diminished by skin rash in a high proportion of patients, often necessitating dose reduction or drug withdrawal. No effective treatment for the rash is available. Methods: We carried out a preliminary investigation on isotretinoin and clindamycin. Among 56 advanced lung cancer patients treated with erlotinib, 31 (53%) developed rash. Seven (35%) of the 20 G2/G3 cases agreed to treatment with clindamycin (450 mg/d, days 1-10; 300 mg/d, days 11-20) plus isotretinoin (20 mg/d, days 11-20) after being informed of the experimental nature of the combination. Results: In 6 of 7 (86%) patients, the rash resolved (G1/G0) without dose reduction; in the other patient (G3), the erlotinib dose also had to be reduced. Median time to resolution was 14 days (range 7-20 days). No rash-treatment adverse events occurred during 20 days of administration. Conclusions: Isotretinoin plus clindamycin promises to be the first effective treatment for erlotinib rash and is being tested further
No
Articolo in rivista - Articolo scientifico
Scientifica
Clindamycin; Erlotinib; Isotretinoin; Nonsmall cell lung cancer; Skin rash;
English
1662
1663
2
Bidoli, P., Cortinovis, D., Colombo, I., Crippa, A., Cicchiello, F., Villa, F., et al. (2010). Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 5(10), 1662-1663 [10.1097/JTO.0b013e3181ec1729].
Bidoli, P; Cortinovis, D; Colombo, I; Crippa, A; Cicchiello, F; Villa, F; Cazzaniga, M; Altomare, G
File in questo prodotto:
File Dimensione Formato  
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.pdf

Solo gestori archivio

Dimensione 473.19 kB
Formato Adobe PDF
473.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/260556
Citazioni
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 15
Social impact